Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium oxide + anhydrous citric acid + sodium picosulfate is an **oral small-molecule combination bowel preparation** developed and marketed by **Ferring** for **colon cleansing prior to colonoscopy** in adults and pediatric patients 9 years of age and older. The regimen combines **sodium picosulfate**, a stimulant laxative prodrug that is converted in the colon to an active metabolite that stimulates colonic peristalsis, with **magnesium oxide + anhydrous citric acid**, which react in solution to form **magnesium citrate**, an osmotic laxative that retains water in the intestinal lumen. Together these mechanisms induce watery diarrhea and rapid evacuation of colonic contents to improve visualization during colonoscopy. The product has been marketed as the powder formulation **Prepopik** and the ready-to-drink oral solution **Clenpiq**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium oxide + anhydrous citric acid + sodium picosulfate.